CytomX Therapeutics, Inc.
CTMX
$2.98
$0.041.36%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -79.85% | -98.26% | -82.16% | -25.71% | 22.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -79.85% | -98.26% | -82.16% | -25.71% | 22.80% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -79.85% | -98.26% | -82.16% | -25.71% | 22.80% |
| SG&A Expenses | 13.41% | 11.31% | -19.19% | -21.12% | 21.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.77% | 26.36% | -25.89% | -40.58% | -5.07% |
| Operating Income | -186.96% | -242.16% | -483.56% | 84.78% | 94.06% |
| Income Before Tax | -177.11% | -239.70% | -344.45% | 98.60% | 70.43% |
| Income Tax Expenses | -4.84% | -12.90% | -4.92% | 23.53% | 26.53% |
| Earnings from Continuing Operations | -177.57% | -240.44% | -348.06% | 97.64% | 70.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -177.57% | -240.44% | -348.06% | 97.64% | 70.58% |
| EBIT | -186.96% | -242.16% | -483.56% | 84.78% | 94.06% |
| EBITDA | -184.42% | -236.09% | -444.36% | 88.25% | 89.76% |
| EPS Basic | -138.11% | -179.01% | -227.89% | 98.44% | 60.62% |
| Normalized Basic EPS | -137.88% | -163.12% | -226.06% | 99.16% | 60.53% |
| EPS Diluted | -138.11% | -179.55% | -233.53% | 98.50% | 60.62% |
| Normalized Diluted EPS | -137.88% | -163.12% | -226.35% | 99.16% | 61.60% |
| Average Basic Shares Outstanding | 103.48% | 97.90% | 93.91% | 52.07% | 6.21% |
| Average Diluted Shares Outstanding | 103.41% | 97.90% | 93.66% | 52.07% | 5.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |